Antiviral Drugs on the Treatment of SARS-CoV-2 (FavRem)

Astana Medical University

Status: Completed

Conditions: Complication of Medical Care; Pneumonia, Viral

Treatments: Drug: Favipiravir; Drug: Remdesivir

Study type: Observational

Funder types: Other

Identifiers

NCT04727775

AMU

Details and patient eligibility

About

Retrospective Non-Randomized Analytical Cohort Study of Completed SARS-CoV2 COVID19 Cases

Full description

Analyzing the case histories of patients with SARS-CoV2 COVID19 infection and the impact on the outcomes of prescribing antiviral drugs

Enrollment: 150 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

main group

• Patients with COVID19 with medium and easy condition disease
• take favipiravir/remdisivir control group
• Patients with COVID19 with medium and easy condition disease
• not take favipiravir/remdisivir

Exclusion criteria

• patients younger 18
• severe conditionis

Trial design

150 participants in 3 patient groups

Complications

Description:

Evaluathion

Treatment:

Drug: Favipiravir

Drug: Remdesivir

Oxygen status

Description:

Evaluathion

Treatment:

Drug: Favipiravir

Drug: Remdesivir

Oxugen support

Description:

Evaluathion

Treatment:

Drug: Favipiravir

Drug: Remdesivir